通过抑制PI3K/AKT通路,作为对三阴性乳腺癌的一种有前途的治疗策略
Shijie Wei1,2, Yubao Zhang3, Xiaoran Ma3
1Institute of Integrated Medicine, Qingdao University, Qingdao, 266071, China.
Scientific reports
|July 31, 2023
概括
从Sophora flavescens衍生出的Matrine通过诱导亡和自,有效地抑制三阴性乳腺癌 (TNBC). 这种天然化合物通过向PI3K/AKT通路,显示出作为TNBC新型治疗剂的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择的侵袭性癌症亚型.
- 传统中国药用草药Sophora flavescens Aiton及其类母体 (MAT) 已显示出抗癌性质.
- 鉴定TNBC的新型治疗剂是研究的一个关键领域.
研究的目的:
- 为了研究母体蛋白 (MAT) 的抗TNBC作用.
- 探索MAT在TNBC细胞中的作用背后的分子机制.
- 评估MAT作为TNBC的潜在治疗剂.
主要方法:
- 对正常和TNBC组织的基因表达数据进行了生物信息学和网络药理学分析.
- 在体外实验中评估了MAT对TNBC细胞增殖,入侵,亡,细胞循环和自的作用.
- 西方涂抹被用来分析PI3K/AKT通路中的关键蛋白质表达.
主要成果:
- 马林 (MAT) 显著抑制了TNBC细胞系 (MDA-MB-231和MDA-MB-468) 的增殖和侵入.
- MAT诱导的细胞循环停止和细胞亡,通过流细胞计和BCL-2的改变表达和分裂的caspase-3得到证实.
- MAT促进了TNBC细胞的自,由MDC染色和LC3-II表达证实,并抑制了PI3K/AKT信号通路.
结论:
- 孕妇 (MAT) 通过抑制细胞增殖和侵入,表现出显著的抗TNBC活性.
- 在TNBC细胞中,MAT诱导了亡和自,同时抑制了TNBC细胞中的PI3K/AKT信号通路.
- 这些发现支持MAT作为三阴性乳腺癌的潜在治疗候选者.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


